Kupando has raised an additional €10M in Series A financing, bringing its total to €23M, to fund Phase 1b trials of KUP101.
Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.
PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 ...
Sepsis remains a major challenge in modern medicine, claiming millions of lives each year. For decades, clinical management has largely focused on suppressing excessive inflammation. Yet many patients ...
From your digestive system to sleep, here are the overlooked signals that indicate your health could be struggling ...
T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...
A new study shows p62-mediated Mallory-Denk body formation is an adaptive, protective response to alcohol-induced liver ...
Morning Overview on MSN
Engineered lipid nanoparticles reprogram immune metabolism to boost mRNA
Researchers are redesigning lipid nanoparticles to do more than shuttle mRNA into cells, with preclinical studies suggesting ...
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) ...
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results